Merck/Schering Terminate Respiratory Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms withdraw NDA for Singulair/Claritin combination.
You may also be interested in...
Merck-Schering Claritin/Singulair Combo “Not Approvable” At FDA
Agency's review of Singulair safety, centered on suicidal thinking and behavior, at issue.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.